This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASH 2021
Presentations

SEA-BCMA | Multiple Myeloma | Abstract #2740
SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Brentuximab Vedotin | Peripheral T-Cell Lymphoma | Abstract #1401
Frontline Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin and Prednisone in Patients With Peripheral T-Cell Lymphoma With Less Than 10% CD30 Expression (SGN35-032, Trial in Progress)

Brentuximab Vedotin | Diffuse Large B-cell Lymphoma | Abstract #3564
Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #2454
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary results from the single-arm phase 2 study (SGN35-027 Part B)

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #1369
Brentuximab Vedotin in Combination With Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients With Early Stage Hodgkin Lymphoma (SGN35-027, Trial in Progress)

SEA-BCMA | Multiple Myeloma | Abstract #1197
Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #2467
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #1966
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)—A Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared by Age

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #1390
Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

Brentuximab Vedotin | Peripheral T-Cell Lymphoma | Abstract #2466
An Oncology Simulation Model to Estimate 10-year Progression-free Survival and Overall Survival Based on the 5-Year Update from the ECHELON-2 Trial in Frontline Patients with Peripheral T-cell Lymphoma: A United States Perspective

Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #2440
An Oncology Simulation Model to Estimate 10-year Progression-free Survival and Stem Cell Transplantation for Frontline Stage IIIor IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective

Brentuximab Vedotin | Peripheral T-Cell Lymphoma | Abstract #135
The ECHELON-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma